10 Prescription Drugs Medicare Is Negotiating First

A long time coming

David Mitchell, founder of Patients for Affordable Drugs Now, has been fighting for lower prescription drug prices for years. Mitchell has an incurable blood cancer, and the drugs he takes carry a combined annual price of almost $1 million. Mitchell’s copays are based on those high prices. One of his drugs, Eliquis, is on the list of drugs being negotiated.

Price negotiations and the other reforms in the new law, Mitchell says, “will improve both the financial well-being and the health of people, more of whom are going to be able to afford to buy and take the drugs they need.”

When Congress first added a prescription drug benefit to Medicare nearly two decades ago, the law explicitly forbade the program to negotiate drug prices with pharmaceutical companies. AARP has been one of the most outspoken advocates for changing that policy. “Medicare negotiates a lot of different services that it covers, and prescription drugs were not a part of that until now,” says Leigh Purvis, AARP’s prescription drug policy principal. “Medicare has tens of millions of beneficiaries and brings a lot of bargaining power to the table and will be able to get better prices for people who are taking these drugs.”

Nearly 52 million Medicare beneficiaries are either enrolled in a Part D prescription drug plan or get drug coverage through their Medicare Advantage plan.

AARP officials Nancy LeaMond, executive vice president and chief advocacy and engagement officer; Leigh Purvis, prescription drug policy principal; Bill Sweeney, senior vice president for government affairs; and Megan O’Reilly, vice president for health and family, attend a White House event to celebrate the release of the first 10 Medicare drugs whose prices will be negotiated with manufacturers.

Rhett Buttle

Patients already benefiting from the new law

While Medicare enrollees will not feel the first effects of negotiated drug prices until 2026, experts point to several other provisions of the new law that are already beginning to save beneficiaries money. Plus, other cost-saving provisions will be rolled out between now and when the negotiated prices kick in. The money the Medicare program saves through those lower prices will enable the program to pay for the provisions that are cutting out-of-pocket costs for beneficiaries.

For example, the $35 cap for Medicare beneficiaries on monthly copays for insulin took effect in 2023, as did free vaccines, including the shingles shot. Another provision that started last year requires drugmakers to pay rebates to Medicare for drugs whose prices increased more than the rate of inflation.

In 2024, beneficiaries with high drug expenses are getting a break from paying any out-of-pocket costs once they reach the so-called catastrophic phase of the Part D prescription drug benefit.

And in 2025, enrollees who either have a stand-alone Part D drug plan or whose prescriptions are covered by their Medicare Advantage plan will see their annual out-of-pocket costs capped at $2,000.

“Collectively, these policies will help lower costs for people on Medicare until the negotiations provision takes effect in 2026,” says Tricia Neuman, senior vice president and head of the Medicare program at KFF, formerly the Kaiser Family Foundation.

Overwhelming support for drug negotiations

For years, polls have shown overwhelming public support for allowing Medicare to negotiate prices. A 2021 KFF public opinion survey found that 83 percent of Americans favored allowing Medicare to negotiate drug prices.

That support crossed party lines, with 92 percent of Democrats, 85 percent of independents and 76 percent of Republicans in favor of price negotiations. A 2022 AARP poll found that 89 percent of voters in the most competitive congressional districts would be more likely to vote for a candidate who backed drug negotiations.

The impact of this new policy will go beyond the savings to Medicare beneficiaries who take the 10 drugs on the initial negotiations list. Medicare is scheduled to choose 15 additional drugs for negotiations, with prices to take effect in 2027, another 15 in 2028 and 20 more medications annually starting in 2029.

“People are feeling the effects of high prescription drug prices through higher premiums and cost sharing, even if you aren’t taking the drugs yourself,” Purvis says. Lower prices for consumers also mean that the Medicare program will save money. The nonpartisan Congressional Budget Office has estimated that the negotiations provision of the new law will save Medicare $98.5 billion over 10 years.

Big drug companies fought against this provision and continue to oppose it. Manufacturers as well as several business groups have filed lawsuits in federal courts across the country in an attempt to derail the negotiation process. AARP and AARP Foundation recently filed a friend of the court legal brief urging a federal judge in Ohio to deny a request by several chambers of commerce that the negotiations process be delayed.

Editor's note: This story, originally published in August 2023, has been updated with new information.